Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-25T07:07:10.063Z Has data issue: false hasContentIssue false
  • English
  • Français

Dyskinesia in Parkinson Disease - An Unmet Therapeutic Challenge

Published online by Cambridge University Press:  02 December 2014

Derek Debicki  and
Mandar Jog
Derek Debicki
Affiliation:
London Health Sciences Centre, London, Ontario, Canada
Mandar Jog
Affiliation:
London Health Sciences Centre, London, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 4 , July 2012 , pp. 414 - 415
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Encarnacion, EV, Hauser, RA.Levodopa-induced dyskinesias in Parkinson’s Disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008;60:57–66.CrossRefGoogle ScholarPubMed
2.Hametner, E, Seppi, K, Poewe, W.The clinical spectrum of levodopa-induced motor complications. J Neurol. 2010;257 Suppl 2: S268–75.CrossRefGoogle ScholarPubMed
3.Gottwald, MD, Aminoff, MJ.Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol. 2011;69:919–27.Google Scholar
4.Jenner, P.Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665–77.CrossRefGoogle ScholarPubMed
5.Iravani, MM, Jenner, P.Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm. 2011;118:1661–90.Google Scholar
6.Ahmed, I, Bose, SK, Pavese, N, et al.Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Brain. 2011;134:979–86.CrossRefGoogle ScholarPubMed
7.Chase, TN, Oh, JD.Striatal dopamine- and glutamate mediated dysregulation in experimental parkinsonism. Trends Neurosci. 2000;23 Suppl 10:S86–91.Google Scholar
8.Hubsher, G, Haider, M, Okun, MS.Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9.Google Scholar
9.Pahwa, R, Factor, SA, Lyons, KE, et al.Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983–95Google Scholar
10.Elahi, B, Phielipp, N, Chen, R.N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci. 2012;39(4):465–72.CrossRefGoogle ScholarPubMed
11.Stathis, P, Konitsiotis, S, Tagaris, G, Peterson, D, VALID-PD Study Group. Levetiracetam for the management of levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord. 2011;26(2):264–70.CrossRefGoogle ScholarPubMed
12.Lane, E, Dunnett, S.Animal models of Parkinson’s disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology. 2008;199(3):303–12.Google Scholar